SK Biopharmaceuticals - Public Comps and Valuation Multiples

SK Biopharmaceuticals Overview

About SK Biopharmaceuticals

SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.

Founded

2011

HQ

Employees

265

Website

skbp.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $475M

LTM EBITDA $142M

EV

$7.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

SK Biopharmaceuticals Financials

As of November 2025, SK Biopharmaceuticals reported last 12-month revenue of $475M and EBITDA of $142M.

In the same period, SK Biopharmaceuticals generated $446M in LTM gross profit and $108M in net income.

See SK Biopharmaceuticals valuation multiples based on analyst estimates

SK Biopharmaceuticals P&L

In the most recent fiscal year, SK Biopharmaceuticals reported revenue of $373M and EBITDA of $68.5M.

SK Biopharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See SK Biopharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$475M	XXX	$373M	XXX	XXX	XXX
Gross Profit	$446M	XXX	$343M	XXX	XXX	XXX
Gross Margin	94%	XXX	92%	XXX	XXX	XXX
EBITDA	$142M	XXX	$68.5M	XXX	XXX	XXX
EBITDA Margin	30%	XXX	18%	XXX	XXX	XXX
EBIT	$135M	XXX	$65.6M	XXX	XXX	XXX
EBIT Margin	29%	XXX	18%	XXX	XXX	XXX
Net Profit	$108M	XXX	$164M	XXX	XXX	XXX
Net Margin	23%	XXX	44%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for SK Biopharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $475M. EBITDA for the last twelve months was $142M. In the most recent fiscal year, SK Biopharmaceuticals achieved $373M in revenue and $68.5M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$475M	Analyst estimates available to subscribers	$373M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$446M	Analyst estimates available to subscribers	$343M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	94.0% gross margin	Analyst estimates available to subscribers	92.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$142M	Analyst estimates available to subscribers	$68.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	29.9% EBITDA margin	Analyst estimates available to subscribers	18.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$135M	Analyst estimates available to subscribers	$65.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	28.5% EBIT margin	Analyst estimates available to subscribers	17.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$108M	Analyst estimates available to subscribers	$164M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	22.8% net profit margin	Analyst estimates available to subscribers	44.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for SK Biopharmaceuticals

This financial data table provides comprehensive performance metrics for SK Biopharmaceuticals, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

SK Biopharmaceuticals generated $475M in revenue over the last twelve months.
The company achieved $142M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $446M.
Net income over the last twelve months reached $108M.

Fiscal Year Performance

In the most recent fiscal year, SK Biopharmaceuticals reported $373M in total revenue.
Fiscal year EBITDA was $68.5M.
The company maintained a gross profit margin of 92.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 18.4%.
Net profit margin reached 44.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for SK Biopharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

SK Biopharmaceuticals Stock Performance

SK Biopharmaceuticals has current market cap of KRW 10.53T (or $7.2B), and EV of KRW 10.33T (or $7.0B).

Market Cap Evolution

SK Biopharmaceuticals Stock Data

As of December 3, 2025, SK Biopharmaceuticals's stock price is KRW 134500 (or $92).

See SK Biopharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$7.0B	$7.2B	XXX	XXX	XXX	XXX	$1.46

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

SK Biopharmaceuticals Valuation Multiples

SK Biopharmaceuticals's trades at 18.9x EV/Revenue multiple, and 102.5x EV/EBITDA.

See valuation multiples for SK Biopharmaceuticals and 15K+ public comps

SK Biopharmaceuticals Financial Valuation Multiples

As of December 3, 2025, SK Biopharmaceuticals has market cap of $7.2B and EV of $7.0B.

Equity research analysts estimate SK Biopharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

SK Biopharmaceuticals has a P/E ratio of 66.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$7.2B	XXX	$7.2B	XXX	XXX	XXX
EV (current)	$7.0B	XXX	$7.0B	XXX	XXX	XXX
EV/Revenue	14.8x	XXX	18.9x	XXX	XXX	XXX
EV/EBITDA	49.5x	XXX	102.5x	XXX	XXX	XXX
EV/EBIT	51.9x	XXX	107.2x	XXX	XXX	XXX
EV/Gross Profit	15.7x	XXX	n/a	XXX	XXX	XXX
P/E	66.2x	XXX	43.8x	XXX	XXX	XXX
EV/FCF	76.9x	XXX	126.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get SK Biopharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

SK Biopharmaceuticals Margins & Growth Rates

SK Biopharmaceuticals's last 12 month revenue growth is 29%

SK Biopharmaceuticals's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.0M for the same period.

SK Biopharmaceuticals's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

SK Biopharmaceuticals's rule of X is 101% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for SK Biopharmaceuticals and other 15K+ public comps

SK Biopharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	29%	XXX	29%	XXX	XXX	XXX
EBITDA Margin	30%	XXX	18%	XXX	XXX	XXX
EBITDA Growth	56%	XXX	n/a	XXX	XXX	XXX
Rule of 40	23%	XXX	47%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	101%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.0M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	9%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	29%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	75%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial